Betuvax-CoB-2 (COVID-19 coronavirus vaccine)

2021: Creation of COVID-19 Betuvax-CoV-2 vaccine

in Moscow Seed Fund early April 2021, he announced the conclusion Human Stem Cell Institute (ISCH) of an agreement with the allocation of a loan to finance research necessary for state the registration and implementation of a new vaccine from COVID-19 the company "" (Betuvaks part of the ISCH group). The total loan amount will be 36 million. rubles

We are talking about the preparation "Betuvax-KoV-2," which the director of the Betuvax company Anna Vakhrusheva called "the first recombinant vaccine of the new generation in Russia based on spherical particles from natural material that mimic viral particles containing the surface antigen (protein) of coronavirus."

Creation in the Russian Federation of a new generation recombinant vaccine based on spherical particles from the natural material "Betuvax-KoV-2"

This vaccine design effectively activates the production of only the necessary protective antibodies, reducing the possible risks of antibody-dependent enhancement of infection (AZU), stimulates cellular immunity. The design of the Betuvax-KoV-2 vaccine also makes it possible to quickly optimize it for new strains of coronavirus and its repeated use, which is a great advantage compared to other analogues, "she explained.

Vakhrusheva also emphasized that the vaccine is not embedded in the body's cells and does not carry genetic material, excessive antigen load, additional preservatives, stabilizers and inorganic adjuvants, which minimizes the risks of side effects.

By the beginning of April 2021, Betuvax is forming a package of documents for the vaccine necessary for its official registration, and is preparing to submit it to the Ministry of Health. Betuvax-CoV-2 is in the process of completing preclinical studies. According to the developers, preclinical studies of the vaccine conducted in animals showed its reliability, safety and effectiveness from COVID-19.^[1]

Notes